TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33012782
Drug: Durvalumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab and gefitinib in combination
Study: 33013302
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks sound therapy using adjusted narrow band sound
Study: 33014443
Drug: Standard bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bandage contact lens (PureVision B&L)
Study: 33015088
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in well-nourished patients
Study: 33015088
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in malnourished patients
Study: 33015088
Drug: Chemotherapy-related toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-related toxicity
Study: 33015104
Drug: Vaginal Lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Lactoferrin administration
Study: 33016100
Drug: Sacubitril/Valsartan (S/V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (S/V) treatment
Study: 33016805
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for symptomatic PAD
Study: 33017106
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (10-day course)
Study: 33017497
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg IV, day 1 every 2 weeks) plus FOLFOX4
Study: 33020594
Drug: TAS-119 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-119 (200 mg BID, 4 days on/3 days off, 3 out of 4 weeks)
Study: 33020594
Drug: TAS-119 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-119 (150, 200, 250, 300 mg BID)
Study: 33020924
Drug: DPYD-guided dose-individualization
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD-guided dose-individualization
Study: 33021872
Drug: Anti-CD19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19 CAR T-cell therapy (FMC63-28Z)
Study: 33022101
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist dose reduction
Study: 33022752
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of educational and environmental interventions
Study: 33023948
Drug: XPO1 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XPO1 inhibitors (selinexor, eltanexor, KOS-2464) combined with melphalan
Study: 33023948
Drug: Single-agent melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent melphalan
Study: 33023948
Drug: XPO1 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XPO1 inhibitors (selinexor, eltanexor) with melphalan
Study: 33023952
Drug: Neoadjuvant enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant enzalutamide plus androgen deprivation therapy (ADT)
Study: 35166065
Drug: Enasidenib 100
Normalized name: enasidenib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib 100 mg once daily
Study: 33025213
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/day for 3 weeks on, 1 week off)
Study: 33025378
Drug: IgPro20 manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 manual push infusion at 0.5 mL/min
Study: 33025378
Drug: IgPro20 manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 manual push infusion at 1.0 mL/min
Study: 33025378
Drug: IgPro20 manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 manual push infusion at 2.0 mL/min
Study: 33025481
Drug: Black carbon
Normalized name: black carbon, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black carbon dye tattooing of biopsied axillary node (2.0 ml median volume injected, range 0.2-4.2 ml)
Study: 33025481
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) group
Study: 33025481
Drug: Timing between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing between dye injection and surgery
Study: 33025482
Drug: Eribulin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin as first- or second-line therapy
Study: 33025707
Drug: L-leucine 700
Normalized name: L-Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-leucine 700 mg/m
Study: 33025716
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg erythromycin infused intravenously over 20 min
Study: 33026753
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% topical solution, administered once daily for 48 weeks
Study: 33026772
Drug: Halobetasol propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol propionate 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Study: 33027528
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with lymphoma- or AL-like regimens followed by transplantation
Study: 33028169
Drug: Prolonged release
Normalized name: EYE DROPS, PROLONGED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release budesonide granules (9 mg daily for 8 weeks)
Study: 33028346
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation followed by 6 cycles of mFOLFOX6 plus avelumab (10 mg/kg) every 2 weeks for 6 cycles.
Study: 33029135
Drug: 30 ml articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml articaine 2%
Study: 33029135
Drug: 30 ml bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml bupivacaine 0.5%
Study: 33030704
Drug: Teicoplanin (weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (weight-based dosing regimen)
Study: 33031046
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Behavioral Activation, 50-minute weekly sessions for 4 weeks using a VR headset
Study: 33031354
Drug: Family-Assisted Severe
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Assisted Severe Febrile Illness Therapy
Study: 33031542
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of venetoclax plus ibrutinib for ≥12 months
Study: 33031809
Drug: Cross-Linking treatment
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-Linking treatment for fungal keratitis
Study: 38479192
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ketamine infusions
Study: 33031955
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg (up to 800 mg) as one intravenous administration, with a second optional administration after 12 hours.
Study: 33032328
Drug: Overall supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall supplement intake
Study: 33032328
Drug: Overall medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall medication use
Study: 33032571
Drug: Cardiovascular medication
Normalized name: CARDIOVASCULAR MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular medication of ticagrelor
Study: 33033101
Drug: Vedolizumab 150
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab 150 mg
Study: 33033101
Drug: Vedolizumab 75
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab 75 mg
Study: 33033101
Drug: Vedolizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (all doses)
Study: 33046517
Drug: CC-90011
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011
Study: 33034295
Drug: Intravital microscopy
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravital microscopy (IVM) during administration of vasopressors or fluid boluses
Study: 33034839
Drug: Ribociclib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (350 mg/m2) administered following radiotherapy in 28-day cycles
Study: 33035333
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T-cell therapy
Study: 33037105
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day gefitinib (oral) and 2.0 mg/m² topotecan
Study: 33037117
Drug: IT MEDI9197
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT MEDI9197 0.005-0.055 mg
Study: 33037117
Drug: IT MEDI9197
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT MEDI9197 0.012 mg plus durvalumab 1500 mg
Study: 33037135
Drug: BI 905711,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 905711, a novel tetravalent bispecific antibody targeting TRAILR2 and CDH17
Study: 33038190
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle.
Study: 33038277
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy with nab-paclitaxel and gemcitabine
Study: 33038286
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg daily
Study: 33038286
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg daily
Study: 33038286
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg daily (patients meeting criteria for dose reduction)
Study: 33038286
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg daily (patients meeting criteria for dose reduction)
Study: 33038346
Drug: Candidate anxiolytics
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate anxiolytics tested in human models of anxiety using anxiety-potentiated startle.
Study: 33039599
Drug: Brigatinib 90
Normalized name: brigatinib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 90 mg daily for 7 days, then escalated to 180 mg daily
Study: 33039812
Drug: Intraperitoneal oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal oxaliplatin delivered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) at a dose of 90 mg/m
Study: 33040013
Drug: VitalScan MCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: VitalScan MCG (Creavo Medical Technologies, UK)
Study: 33040383
Drug: Omnipod Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipod Insulin Management System
Study: 33042202
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) and aromatase inhibitor therapy (AIT)
Study: 33042579
Drug: IV infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of 4 mg/kg tocilizumab (TCZ)
Study: 33042579
Drug: IV infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of 8 mg/kg tocilizumab (TCZ)
Study: 33043164
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg, up to 800 mg, single shot)
Study: 33043304
Drug: 3 to
Normalized name: Melquin-3 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 to 4 cycles of BEP chemotherapy (high-intensity cisplatin)
Study: 33044566
Drug: Ensartinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib (200 mg/100 μCi)
Study: 33045316
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wP) at 80 mg/m² for 6 weeks + Low-dose fractionated whole abdominal radiation therapy (LDFWART)
Study: 33045496
Drug: Ocrelizumab 600-mg
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600-mg Dose 2 or 3 infused over approximately 2 hours (Cohort 1)
Study: 33045496
Drug: Ocrelizumab 300-mg
Normalized name: ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 300-mg Dose 1, Infusion 2 over approximately 1.5 hours (Cohort 2)
Study: 35611270
Drug: Laser interstitial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser interstitial thermal therapy (LITT)
Study: 33045994
Drug: Shifts from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts from low/high to middle category (L-M/H-M) for phosphorus
Study: 33045994
Drug: Shifts from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts from middle to low/high category (M-L/M-H) for phosphorus
Study: 33045994
Drug: Shifts from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts from low/middle to high category (L-H/M-H) for calcium
Study: 33045994
Drug: Shifts from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts from low to middle category (L-M) for intact parathyroid hormone
Study: 33046066
Drug: daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral pre-exposure prophylaxis (PrEP)
Study: 33046066
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ART-VL plus PrEP
Study: 33046513
Drug: Single intratumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratumoral injection
Study: 33046518
Drug: Geptanolimab (GB226)
Normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geptanolimab (GB226) administered intravenously at a dosage of 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Study: 33046517
Drug: CC-90011 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 at 60 mg once per week (RP2D)
Study: 33046517
Drug: CC-90011 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 at 120 mg once per week (NTD)
Study: 33046517
Drug: CC-90011 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 at 80 mg once per week (MTD)
Study: 33046621
Drug: AMG 820
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 820 (1100 mg or 1400 mg) plus pembrolizumab (200 mg) intravenously every 3 weeks
Study: 33046765
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications with a reduction in hsCRP levels of 40% or greater (responder group)
Study: 33046765
Drug: Antihypertensive medications
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medications with a reduction in hsCRP levels of less than 40% (non-responder group)
Study: 33046868
Drug: Autologous NKT
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous NKT cells engineered to co-express a GD2-specific chimeric antigen receptor (CAR) with interleukin-15
Study: 33046870
Drug: Preoperative immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies
Study: 33046998
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin, dosage based on weight, D-dimer levels, and clinical condition.
Study: 33047248
Drug: IntraOmmaya antiGD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IntraOmmaya antiGD2 monoclonal antibody
Study: 33047329
Drug: Dose adjustments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustments to 40 mg/day for IM patients and 80 mg/day for PM patients
Study: 33047329
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase to 60 mg/day for PM patients
Study: 33047816
Drug: Dental isolation
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental isolation combination system (Isolite)
Study: 33048057
Drug: Remote titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote titration facilitated by telemonitoring using a smartphone-based system
Study: 33048057
Drug: Standard titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titration program consisting of in-office visits
Study: 33048203
Drug: Ravulizumab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (loading dose on Day 1, maintenance doses every 4-8 weeks)
Study: 33048619
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy antitumor activity in underexplored cancer types (specific treatments not detailed)
Study: 33050804
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) - sunitinib, pazopanib, sorafenib
Study: 33051036
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) for 6 months
Study: 33051234
Drug: Weekly community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly community dance sessions designed for people with breathlessness, lasting 75 min, led by a trained community dance leader.
Study: 33051264
Drug: Belimumab plus
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab plus standard therapy
Study: 33051855
Drug: Montreal museum
Normalized name: BCG, live, Montreal strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montreal museum of fine arts (MMFA) participatory art-based activities, one weekly structured workshop over a 3-month period.
Study: 33052476
Drug: Delay to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay to oral feeding
Study: 33052556
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg plus gefitinib 250 mg orally once daily
Study: 33054114
Drug: Pediatric-inspired chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric-inspired chemotherapy incorporating 6 doses of pegaspargase 2000 IU/m2
Study: 33054130
Drug: CC variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC variant
Study: 33055233
Drug: Diabetic foot
Normalized name: Zostrix Diabetic Foot Pain
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic foot ulcer prevention program with once-daily foot temperature monitoring
Study: 33055274
Drug: Non-aspirin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin group
Study: 33057634
Drug: D-dimer testing
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer testing followed by whole-leg compression ultrasonography (CUS) for patients with positive D-dimer (≥0.5 µg/mL)
Study: 33058182
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (n=86)
Study: 33058182
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=68)
Study: 33060077
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg every 3 weeks for three cycles)
Study: 33060149
Drug: HX008 200
Normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX008 200 mg intravenously every 3 weeks plus irinotecan 160 mg/m²
Study: 33060506
Drug: Osmotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic therapy administration
Study: 33061494
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group)
Study: 33061494
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group)
Study: 33061500
Drug: Anthocyanins (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (320 mg/day)
Study: 33062236
Drug: Proprotein convertase
Normalized name: Proprotein convertase 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy
Study: 33062627
Drug: YH4808 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (novel selective potassium-competitive acid blocker)
Study: 33062629
Drug: Tofacitinib aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib aspartate 7.13 mg (test formulation)
Study: 33062629
Drug: Tofacitinib citrate
Normalized name: Tofacitinib Citrate
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib citrate 8.08 mg (reference formulation)
Study: 33062947
Drug: Nivolumab 40 mg
Normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 40 mg every 2 weeks